SCHEMBL3327259

SCHEMBL3327259

Cc1c(Cc2ccc3cc(F)ccc3n2)c2cc(C#N)ccn2c1CC(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 7/20 0.42
PTGDR Q13258 2/20 0.42
PTGIR P43119 1/20 0.42
LIPG Q9Y5X9 1/20 0.34
PDE10A Q9Y233 3/20 0.33
HDAC1 Q13547 2/20 0.33
HDAC2 Q92769 2/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
ALOX5AP P20292 1/20 0.31
HDAC3 O15379 1/20 0.31
CYP3A4 P08684 1/20 0.31
HDAC4 P56524 1/20 0.31
HDAC7 Q8WUI4 1/20 0.31
HDAC10 Q969S8 1/20 0.31
HDAC11 Q96DB2 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
HDAC9 Q9UKV0 1/20 0.31
HDAC5 Q9UQL6 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3327331 0.90 PTGIR (0.36) PTGDR2PTGDRPTGIRPDE10AHDAC1
SCHEMBL4636883 0.86 PTGDR2 (0.44) PTGDR2PTGDRPTGIRPDE10AHDAC1
SCHEMBL3567666 0.80 PTGDR2 (0.42) PTGDR2PTGDRPTGIRLIPGPDE10A
SCHEMBL4636112 0.76 PTGIR (0.38) PTGDR2PTGDRPTGIRPDE10AHDAC1
SCHEMBL4636743 0.74 PTGES (0.38) PTGDR2MEN1KMT2ACYP3A4
SCHEMBL3577485 0.72 TSHR (0.38) PTGDR2PTGDRPTGIRPDE10AMEN1
SCHEMBL4636233 0.72 PTGDR2 (0.41) PTGDR2
SCHEMBL14176165 0.72 PTGDR2 (0.44) PTGDR2PTGDRPTGIRPDE10AHDAC1
SCHEMBL3968540 0.69 PTGDR2 (0.47) PTGDR2PTGDR
SCHEMBL3570506 0.68 PTGES (0.40) PTGDR2MEN1KMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137300-A1 Indolizine Acetic Acid Derivatives as CRTH2 Antagonists ARGENTA ORAL THERAPEUTICS LIMITED (GB) 2010-06-03 US claimed
EP-2136804-A1 INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS Argenta Oral Therapeutics Limited (GB) 2009-12-30 EP claimed
WO-2008113965-A1 INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS ARGENTA DISCOVERY LIMITED (GB) 2008-09-25 WO claimed
US-20100137300-A1 Indolizine Acetic Acid Derivatives as CRTH2 Antagonists ARGENTA ORAL THERAPEUTICS LIMITED (GB) 2010-06-03 US disclosed
US-20100137300-A1 Indolizine Acetic Acid Derivatives as CRTH2 Antagonists ARGENTA ORAL THERAPEUTICS LIMITED (GB) 2010-06-03 US disclosed
US-20100137300-A1 Indolizine Acetic Acid Derivatives as CRTH2 Antagonists ARGENTA ORAL THERAPEUTICS LIMITED (GB) 2010-06-03 US disclosed
US-20100137300-A1 Indolizine Acetic Acid Derivatives as CRTH2 Antagonists ARGENTA ORAL THERAPEUTICS LIMITED (GB) 2010-06-03 US disclosed
CN-101678009-A Indolizine acetic acid derivatives as CRTH2 antagonists ARGENTA DISCOVERY LTD 2010-03-24 CN disclosed
EP-2136804-A1 INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS Argenta Oral Therapeutics Limited (GB) 2009-12-30 EP disclosed
EP-2136804-A1 INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS Argenta Oral Therapeutics Limited (GB) 2009-12-30 EP disclosed
WO-2008113965-A1 INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS ARGENTA DISCOVERY LIMITED (GB) 2008-09-25 WO disclosed
WO-2008113965-A1 INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS ARGENTA DISCOVERY LIMITED (GB) 2008-09-25 WO disclosed
WO-2008113965-A1 INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS ARGENTA DISCOVERY LIMITED (GB) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137300-A1 Indolizine Acetic Acid Derivatives as CRTH2 Antagonists HRH1, HRH4, HRH2 PTGDR2 826/4885PTGDR 927/4885PTGIR 1666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.